{"id":519753,"date":"2021-07-29T07:33:25","date_gmt":"2021-07-29T11:33:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/"},"modified":"2021-07-29T07:33:25","modified_gmt":"2021-07-29T11:33:25","slug":"strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/","title":{"rendered":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DUBLIN, Ireland and TREVOSE, Pa., July  29, 2021  (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company\u2019s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET.<\/p>\n<p align=\"justify\">\n        <strong>About Strongbridge Biopharma<\/strong><br \/>\n        <br \/>Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV<sup>\u00ae<\/sup>\u00a0(levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing\u2019s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The company\u2019s rare neuromuscular franchise includes KEVEYIS<sup>\u00ae<\/sup>\u00a0(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Corporate and Media Relations<\/strong><br \/>\n        <br \/>Elixir Health Public Relations<br \/>Lindsay Rocco<br \/>+1 862-596-1304<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MvBCsTay9DnsqhROCE_yA0nWwS5JZJARM6QmHhotJ0xz_wkj759RdWrwsdkfUxR4aTR87gs02MI9ki5GlH-Ag-BhbhV7l3r5Awb9d8Kjw5I=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>lrocco@elixirhealthpr.com<\/strong><\/a><\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Solebury Trout<br \/>Mike Biega<br \/>+1 617-221-9660<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ogM-X6MeVMgdcTiZAfNgRXdpw786KWW2Cniacp6na-E97kTdratrdBljNVKtSu78ndoVaJocQXbj5CWklsjmOdmcAeIEW_KXNeQPBtj5bxc=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>mbiega@soleburytrout.com<\/strong><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6f63d297-2523-4550-a7b7-7a23aa88e1df\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company\u2019s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET. About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae\u00a0(levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing\u2019s syndrome, and veldoreotide extended release, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519753","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company\u2019s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET. About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae\u00a0(levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing\u2019s syndrome, and veldoreotide extended release, &hellip; Continue reading &quot;Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T11:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021\",\"datePublished\":\"2021-07-29T11:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/\"},\"wordCount\":230,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/\",\"name\":\"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\",\"datePublished\":\"2021-07-29T11:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/","og_locale":"en_US","og_type":"article","og_title":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk","og_description":"DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company\u2019s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET. About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge\u2019s rare endocrine franchise includes RECORLEV\u00ae\u00a0(levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing\u2019s syndrome, and veldoreotide extended release, &hellip; Continue reading \"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T11:33:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021","datePublished":"2021-07-29T11:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/"},"wordCount":230,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/","name":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=","datePublished":"2021-07-29T11:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc1OSM0MzE3OTAwIzIwMjAwMjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-to-report-second-quarter-2021-financial-results-on-august-5-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519753"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}